A double-blind, placebo-controlled pilot study of ondansetron for patients with
Author(s): Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I.
Affiliation(s): Department of Anesthesiology, Jundishapur University of Medical Sciences, Ahwaz,
Publication date & source: 2010, Hum Psychopharmacol. , 25(6):509-13
OBJECTIVE: To assess the efficacy and tolerability of ondansetron in combination
with selective serotonin reuptake inhibitors (SSRIs) in patients with
obsessive-compulsive disorder (OCD).
METHODS: The study was an 8-week pilot double-blind randomized clinical trial.
Forty-two adult outpatients who met the Diagnostic and Statistical Manual, Fourth
Edition, Text Revision (DSM-IV-TR) criteria for OCD based on the structured
clinical interview participated in the trial. In this study, patients were
randomly assigned to receive either ondansetron (4 mg) plus fluoxetine or
fluoxetine (20 mg/day) plus placebo.
RESULTS: The results showed a significant difference between two groups in the
treatment of OCD (based on t-test). There was not any significant difference
between the two groups in terms of observed side effects.
CONCLUSIONS: The results of this study show that ondansetron has positive effects
on obsession and compulsion which start two weeks after the beginning of the